Construction of a Prefabricated Modular Building for a Thermal Disinfection and Decontamination Station for Pathogenicity Groups III–IV Effluents

The milestone V All-Russian GMP Conference officially launched on September 30, 2020, successfully transitioning to a fully virtual format. Despite the international travel restrictions caused by the COVID-19 pandemic, the event preserved its international status, featuring regulators from 16 foreign nations and representatives from all EAEU member states on its opening day.

The digital transition proved to be a catalyst for engagement, attracting nearly 2,500 industry professionals. During the peak sessions, more than 1,500 viewers simultaneously engaged with live broadcasts streamed from a high-tech television studio in Moscow.

A Strategic Vision for Healthcare: The conference opened with a personal welcome from the Minister of Industry and Trade of the Russian Federation, Denis Manturov. Under the motto "Unified GxP Rules — Quality for the Benefit of Health," the forum highlighted that the quality of medicines and medical devices must remain uncompromised even during global crises.

Key Discussion Pillars:

• Crisis Management: Addressing the surge in demand for critical care medications such as anesthetics, antibiotics, and medical oxygen.

• Remote Inspections: Industry leaders, including MSD and Roche, shared their successful experiences passing virtual GMP inspections during lockdowns—a new standard in regulatory oversight.

• Unified Market: Strategies for transitioning to unified EAEU registration rules and assessments of national producers' competence in manufacturing full-cycle Active Pharmaceutical Substances (APS).

• International Cooperation: For the first time, an OECD representative participated, alongside strategic meetings between Russian pharma companies and trade missions from China, India, Brazil, Morocco, Cuba, and the Netherlands.

Collaborative Industry Support: The success of the 2020 anniversary event was made possible through strong industry partnerships:

• General Partner: MSD Pharmaceuticals.

• Strategic Partners: Gedeon Richter and Roche.

• Official Partners: Teva, Astellas Pharma, and Amgen.

• Special Partners: Abbott and Natsimbio.

The conference was organized by the Ministry of Industry and Trade of the Russian Federation in collaboration with FSI "SID & GP", with S-Group serving as the official operator.